Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.42 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | VHL | P40337 | 1/20 | 0.35 |
| ▸ | SELE | P16581 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250847 | 1.00 | ATM (0.61) | ATMACECHRNB2CHRNA3CHRNA4 | |
| SCHEMBL2032328 | 1.00 | ATM (0.61) | ATMACECHRNB2CHRNA3CHRNA4 | |
| SCHEMBL4252592 | 1.00 | ATM (0.61) | ATMACECHRNB2CHRNA3CHRNA4 | |
| SCHEMBL2032330 | 1.00 | ATM (0.61) | ATMACECHRNB2CHRNA3CHRNA4 | |
| SCHEMBL4258847 | 1.00 | ATM (0.61) | ATMACECHRNB2CHRNA3CHRNA4 | |
| SCHEMBL4250843 | 1.00 | ATM (0.61) | ATMACECHRNB2CHRNA3CHRNA4 | |
| SCHEMBL28993935 | 0.89 | ATM (0.56) | ATMACESELEALDH1A1 | |
| SCHEMBL28993936 | 0.89 | ATM (0.56) | ATMACESELEALDH1A1 | |
| SCHEMBL396912 | 0.87 | ATM (0.54) | ATMACEALDH1A1 | |
| SCHEMBL31222356 | 0.87 | ATM (0.54) | ATMACEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111632095-A | Antibacterial vagina tightening and contracting composition and application thereof | 上海赫依美容美体有限公司 | 2020-09-08 | — | — | CN | disclosed |
| US-8338404-B2 | Composition and method for reducing allergen | KYOWA HAKKO BIO CO., LTD. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20090069403-A1 | COMPOSITION AND METHOD FOR REDUCING ALLERGEN | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20080188546-A1 | Preventive or therapeutic agents for decubitus | TAKEDA TOSHIAKI | 2008-08-07 | — | — | US | disclosed |
| US-20080102042-A1 | Dentifrices containing N-acyl derivative of hydroxyproline; periodontal disease | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20070293559-A1 | Orally Administered Agent For Preventing Or Improving Dry Station Of Skin | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1795191-A1 | ORAL PHARMACEUTICAL FOR DRY SKIN PREVENTION OR REMEDY | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-20060034781-A1 | PERORAL PREPARATION FOR PREVENTION OR TREATMENT OF ATOPIC DERMATATIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-02-16 | — | — | US | disclosed |
| US-20060035957-A1 | Preventive or remedy for bedsore | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-02-16 | — | — | US | disclosed |
| EP-1559425-A1 | PERORAL PREPARATION FOR PREVENTION OF OR TREATMENT FOR ATOPIC DERMATITIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-08-03 | — | — | EP | disclosed |
| EP-1547594-A1 | PREVENTIVE OR REMEDY FOR BEDSORE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-20030185864-A1 | Preventives or remedies for atopic dermatitis | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1304323-A1 | PREVENTIVES OR REMEDIES FOR ATOPIC DERMATITIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069403-A1 | COMPOSITION AND METHOD FOR REDUCING ALLERGEN | TSLP, CARM1, CMA1 | ATM 2585/4885ACE 103/4885CHRNB2 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.